Journals / Pediatric Practice and Research / 2021 / Cilt: 9 - Sayı: 3

The Effect of Long-Term Valproic Acid Monotherapy on Hematological and Biochemical Parameters in Children with Epilepsy

Epilepsi Tanılı Çocuklarda Uzun Süreli Valproik Asit Monoterapisinin Hematolojik Ve Biyokimyasal Parametreler Üzerine Etkisi

Pages
102–108
Publication Date
2021-12-31
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Therefore, baseline measurement of liver function and haematological parameters and monitoring during therapy is recommended.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The aim of this study is to determine the long-term hematological and biochemical side effects of valproic acid (VPA) in pediatric patients with epilepsy.
📊
Key Findings & Data:Results: Eighty-five patients aged 3-18 (mean 10.52 ± 3.63) met the study criteria. 50 (58.9%) of the patients were girls.
💡
Conclusion & Impact:Therefore, baseline measurement of liver function and haematological parameters and monitoring during therapy is recommended.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:valproik asit · yan etkiler · hematolojik

Abstract

Objective: The aim of this study is to determine the long-term hematological and biochemical side effects of valproic acid (VPA) in pediatric patients with epilepsy. Materials and Methods: A retrospective natural study design was used. Participants were pediatric patients with epilepsy who were treated with VPA only as monotherapy. Electronic medical files were reviewed for changes in hematological and biochemical parameters before and after a VPA treatment. Results: Eighty-five patients aged 3-18 (mean 10.52 ± 3.63) met the study criteria. 50 (58.9%) of the patients were girls. In the second year after starting the treatment, the platelet values of the patients were calculated as 249.32 ± 48.778 in patients using VPA, and this difference over the years is statistically significant. No serious side effects were reported. Conclusion: Epileptic patients treated with VPA may be at risk of decreased platelet count and elevated liver enzymes. Therefore, baseline measurement of liver function and haematological parameters and monitoring during therapy is recommended.

Özet

Amaç: Bu çalışmanın amacı epilepsi tanılı çocuk hastalarda valproik asidin (VPA) uzun süreli hematolojik ve biyokimyasal yan etkilerini belirlemektir. Gereç ve Yöntem: Geriye dönük bir doğal çalışma tasarımı kullanılmıştır. Katılımcılar, monoteratpi şeklinde yalnızca VPA ile tedavi edilen epilepsi saptanan çocuk hastalardı. Elektronik tıbbi dosyalar, bir VPA tedavisi öncesi ve sonrasında hematolojik ve biyokimyasal parametrelerdeki değişiklikler için gözden geçirildi. Bulgular: Yaşları 3-18 (ort. 10,52 ± 3,63) olan 85 hasta çalışma kriterlerini karşıladı. Hastaların 50’sini (%58,9) kızlar oluşturmaktaydı. Tedaviye başladıktan sonraki ikinci yılda hastaların Trombosit değerleri VPA kullanan hastalarda ortalama 249,32 ± 48,778 olarak hesaplanmıştır ve yıllar içindeki bu farklılık istatistiksel olarak anlamlıdır. Hiçbir ciddi yan etki bildirilmedi. Sonuç: VPA ile tedavi edilen epileptik hastalar, trombosit sayısında azalma ve karaciğer enzimlerinde yükselme riski altında olabilir. Bu nedenle, karaciğer fonksiyonlarının ve hematolojik parametrelerin temel ölçümü ve tedavi boyunca izlenmesi önerilir.

🔖

Cite This Article

KAYIS, E., YILMAZ, R., KARAASLAN, E. (2021). The Effect of Long-Term Valproic Acid Monotherapy on Hematological and Biochemical Parameters in Children with Epilepsy. Pediatric Practice and Research, Cilt: 9 - Sayı: 3, 102–108. https://ajindex.com/articles/795344

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Davis R, Peters DH, McTavish D. Valproic acid. A reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs 1994;47:332-72
  2. Tran AR, Zito JM, Safer DJ, Hundley SD. National trends in pediatric use of anticonvulsants. Psychiatr Serv 2012;63:1095-101
  3. Belcastro V, D'Egidio C, Striano P, Verrotti A. Metabolic and endocrine effects of valproic acid chronic treatment. Epilepsy Res 2013;107:1-8
  4. Kayış E, Yılmaz R, Karaaslan E. Childhood Epilepsy and Valproic Acid and Carbamazepine Treatment: Childhood Epilepsy. Chronicles of Precision Medical Researchers 2020;1:34-44
  5. Abaci A, Saygi M, Yis U, Demir K, Dirik E, Bober E. Metabolic alterations during valproic acid treatment: a prospective study. Pediatr Neurol 2009;41:435-9
  6. Aggarwal A, Rastogi N, Mittal H, Chillar N, Patil R. Thyroid hormone levels in children receiving carbamazepine or valproate. Pediatr Neurol 2011;45:159-62
  7. Aygün F, Ekici B, Aydinli N, Aydin BK, Baş F, Tatli B. Thyroid hormones in children on antiepileptic therapy. Int J Neurosci 2012;122:69-73
  8. Voudris K, Attilakos A, Katsarou E, et al. Serum total amylase, pancreatic amylase and lipase activities in epileptic children treated with sodium valproate monotherapy. Brain Dev 2006;28:572-5
  9. Gerstner T, Büsing D, Bell N, et al. Valproic acid-induced pancreatitis: 16 new cases and a review of the literature. J Gastroenterol 2007;42:39-48
  10. Grauso-Eby NL, Goldfarb O, Feldman-Winter LB, McAbee GN. Acute pancreatitis in children from Valproic acid: case series and review. Pediatr Neurol 2003;28:145-8
  11. Schmid MM, Freudenmann RW, Keller F, et al. Non-fatal and fatal liver failure associated with valproic acid. Pharmacopsychiatry 2013;46:63-8
  12. Geller B, Luby JL, Joshi P, et al. A randomized controlled trial of risperidone, lithium, or divalproex sodium for initial treatment of bipolar I disorder, manic or mixed phase, in children and adolescents. Arch Gen Psychiatry 2012;69:515-28
  13. Pavuluri MN, Henry DB, Carbray JA, Sampson G, Naylor MW, Janicak PG. Open-label prospective trial of risperidone in combination with lithium or divalproex sodium in pediatric mania. J Affect Disord 2004;82 Suppl 1:S103-11
  14. Brigo F, Igwe SC, Lattanzi S. Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. Cochrane Database Syst Rev 2021;1:Cd003032
  15. Tolou-Ghamari Z, Zare M, Habibabadi JM, Najafi M-R. Antiepileptic drugs: a consideration of clinical and biochemi